AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2809781
Drug: Intravenous dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous dexamethasone (0.25 mg/kg)
Trial: 31594919
Drug: Pomalidomide (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomalidomide (4 mg daily for 21 days every 4 weeks) and dexamethasone (40 mg weekly)
Trial: 31594919
Drug: Pomalidomide (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomalidomide (4 mg daily for 21 days every 4 weeks) and dexamethasone (40 mg weekly) + cyclophosphamide (300 mg/m2 if less than minimal response after three cycles)
Trial: 31594919
Drug: Pomalidomide and
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pomalidomide and dexamethasone combination
Trial: 31594919
Drug: Pomalidomide and
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pomalidomide and dexamethasone combination with cyclophosphamide
Trial: 19397474
Drug: low sodium
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low sodium + 100mg losartan + 25 mg hydrochlorothiazide
Trial: 17142656
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam 0.5 mg·kg-1 po administered 20-30 min preoperatively
Trial: 8617997
Drug: 1 alpha,25(OH)2D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 alpha,25(OH)2D3 (15 microgram/g Vaseline)
Trial: 1958442
Drug: Slow release
RxNorm normalized name: Slow Release Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow release nicotinic acid formulation (500 mg)
Trial: 1958442
Drug: Rapid-release nicotinic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid-release nicotinic acid formulation (500 mg)
Trial: 7082061
Drug: Patient-controlled analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled analgesia (PCA) device with intravenous morphine sulfate
Trial: 7082061
Drug: Standard intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intramuscular dosages of morphine sulfate
Trial: 7082061
Drug: Morphine usage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine usage in PCA group
Trial: 19563061
Drug: Yasmin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yasmin (30 microg ethinylestradiol plus 3 mg drospirenone)
Trial: 11605110
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group (local anesthesia)
Trial: 11907935
Drug: Conpremin (0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conpremin (0.625 mg tablets)
Trial: 11907935
Drug: Generic conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Generic conjugated estrogens (0.625 mg tablets)
Trial: 7862712
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg cocaine IV on day 1, 25 mg cocaine IV on day 2
Trial: 7862712
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion on day 1, saline infusion on day 2
Trial: 31832992
Drug: Buccal infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal infiltration (BI) using 4% articaine
Trial: 18033629
Drug: Daily 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily 10 mg alendronate and calcium
Trial: 18033629
Drug: Every other
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every other day 10 mg alendronate and calcium
Trial: 18033629
Drug: Daily 200
RxNorm normalized name: Culturelle Probiotics Digestive Daily 200mg-10 Billion CFU Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily 200 IU calcitonin and calcium
Trial: 11322350
Drug: Extended-release oxybutynin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release oxybutynin, 10 mg/d
Trial: 24895382
Drug: Hydrotherapy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrotherapy treatment
Trial: 9408932
Drug: Land treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Land treatment
Trial: 2878746
Drug: Insulin (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (0.1 IU/kg body weight)
Trial: 31240998
Drug: Computerized WCST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerized WCST administration
Trial: 31240998
Drug: Manual WCST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual WCST administration
Trial: 31240998
Drug: Manual and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual and Computerized WCST administration
Trial: 27633823
Drug: ePROM questionnaire
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ePROM questionnaire completed monthly
Trial: 18930226
Drug: GnRH antagonists
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonists and recombinant FSH in the luteal phase (group II)
Trial: 17573794
Drug: Polyethylene glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol (PEG) 3350, 17 g daily for 28 days
Trial: 17573794
Drug: Tegaserod, 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegaserod, 6 mg b.i.d. for 28 days
Trial: 2522746
Drug: Epidural injection
RxNorm normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural injection of 10 ml of autologous blood
Trial: 6195761
Drug: Cefuroxime and
RxNorm normalized name: cefuroxime and metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime and Cefotaxim (antibiotic prophylaxis)
Trial: 30229999
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D deficiency (<10 ng/mL)
Trial: 30229999
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D sufficiency (>20 ng/mL)
Trial: 28512725
Drug: Clofibrate (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clofibrate (50 mg/kg single dose prior to phototherapy)
Trial: 30415813
Drug: Dutasteride 0.5
RxNorm normalized name: dutasteride 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dutasteride 0.5 mg/d
Trial: 15839466
Drug: Optimised formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimised formulation of mefloquine (Mephaquin Lactabs/Test)
Trial: 12495804
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg buprenorphine
Trial: 12495804
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg buprenorphine
Trial: 8091360
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg per day of lisinopril
Trial: 8091360
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 20 mg of lisinopril and 12.5 mg of hydrochlorothiazide per day
Trial: 73903
Drug: Effervescent activated
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effervescent activated charcoal (10 g packet containing 5 g activated charcoal) administered 30 min after 75 mg nortriptyline
Trial: 73903
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of effervescent activated charcoal
Trial: 25810066
Drug: Isosorbide mononitrate
RxNorm normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide mononitrate (ISMN, 60 mg single dose, day 5) with cortisol (200 mg per day, days 1-6)
Trial: 25810066
Drug: Cortisol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisol (200 mg per day, days 1-6) with placebo (single dose, day 5)
Trial: 21670611
Drug: Intraperitoneal local
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal local anesthetic (IPLA) - ropivacaine 75 mg instillation before dissection and 0.2% solution at 4 mL/hour for 3 days postoperative infusion
Trial: 21670611
Drug: Placebo -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - 0.9% saline solution instillation and infusion
Trial: 19553646
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (including rescue PCI or delayed angiography)
Trial: 16113435
Drug: Corticosteroid/beta(2)‐agonist combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid/beta(2)‐agonist combination therapy
Trial: 9881552
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg oral ciprofloxacin eight hours before surgery
Trial: 7770137
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anaesthesia (TIVA) with midazolam and alfentanil
Trial: 7770137
Drug: Conventional inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional inhalation anaesthesia
Trial: 2457006
Drug: 4 cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 cycles of ABVD chemotherapy
Trial: 2457006
Drug: 2 cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 cycles of MOPP + 2 cycles of ABVD chemotherapy
Trial: 2457006
Drug: Irradiation at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irradiation at a low dose (20 Gy) for good responders
Trial: 31642426
Drug: Double filtration
RxNorm normalized name: SNAIL SECRETION FILTRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double filtration plasmapheresis (DFPP) combined with methylprednisolone (MP) and cyclophosphamide (CTX) pulse therapy
Trial: 31642426
Drug: Methylprednisolone (MP)
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (MP) and cyclophosphamide (CTX) pulse therapy
Trial: 19233003
Drug: 7.5 mL
RxNorm normalized name: 7.5 ML Spevigo 60 MG/ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mL of 3.5% lidocaine dissolved in fibrin glue (Group A)
Trial: 19233003
Drug: 7.5 mL
RxNorm normalized name: 7.5 ML Spevigo 60 MG/ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mL of lidocaine alone (Group B)
Trial: 19233003
Drug: 7.5 mL
RxNorm normalized name: 7.5 ML Spevigo 60 MG/ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mL of fibrin glue alone (Group C)
Trial: 9330125
Drug: Carvedilol (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (up to 25 mg twice daily, n = 70)
Trial: 12885812
Drug: Paclitaxel 100
RxNorm normalized name: paclitaxel 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel 100 mg/m2 weekly for 3 of 4 weeks with carboplatin (AUC = 6)
Trial: 12885812
Drug: Paclitaxel 100
RxNorm normalized name: paclitaxel 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel 100 mg/m2 and carboplatin (AUC = 2) weekly for 3 of 4 weeks
Trial: 12885812
Drug: Paclitaxel 150
RxNorm normalized name: paclitaxel 150 MG per 25 ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel 150 mg/m2 cycle 1 and 100 mg/m2 cycle 2 and carboplatin (AUC = 2) weekly for 6 of 8 weeks
Trial: 12885812
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel therapy (70 mg/m2, 3 of 4 weeks)
Trial: 10553410
Drug: Regimen A
RxNorm normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen A (CDDP 16 mg/m2 for 5 days, 5-FU 600 mg/m2/day for 120 hours)
Trial: 10553410
Drug: Regimen B
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen B (CDDP 80 mg/m2 on day 1, 5-FU 600 mg/m2/day for 120 hours)
Trial: 8897078
Drug: 95 mg
RxNorm normalized name: aspirin 195 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 95 mg metoprolol and 40 mg pantoprazole (test)
Trial: 8897078
Drug: 95 mg
RxNorm normalized name: aspirin 195 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 95 mg metoprolol and placebo (reference)
Trial: 31434775
Drug: German Unidimensional
RxNorm normalized name: German cockroach allergenic extract
DrugBank: Blatella germanica (DB10418)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: German Unidimensional Self‐Efficacy Scale for Multiple Sclerosis (USE‐MS-G)
Trial: 26077874
Drug: DHA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA supplementation (500 mg) with iron tablet
Trial: 26077874
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with iron tablet
Trial: 16109986
Drug: Two-implant overdentures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-implant overdentures (IOD)
Trial: 10709119
Drug: r‐HuEPO 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r‐HuEPO 400 units/kg every alternate day for 10 doses
Trial: 2183056
Drug: Tetrahydroaminoacridine (THA)
RxNorm normalized name: Tetrahydroaminoacridine
DrugBank: Tacrine (DB00382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetrahydroaminoacridine (THA) 100 mg per day
Trial: 28558384
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg intravenous paracetamol
Trial: 28558384
Drug: 15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg intravenous paracetamol
Trial: 28558384
Drug: 20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg intravenous paracetamol
Trial: 28558384
Drug: Intravenous paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous paracetamol (all doses combined)
Trial: 28558384
Drug: Oral sucrose
RxNorm normalized name: TootSweet 24% Oral Sucrose Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sucrose (control group)
Trial: 19134454
Drug: Flunarizine Capsules
RxNorm normalized name: flunarizine
DrugBank: Flunarizine (DB04841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunarizine Capsules
Trial: 16702322
Drug: High flavanol
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High flavanol cocoa (326 mg/d)
Trial: 16702322
Drug: Low flavanol
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low flavanol cocoa (27 mg/d)
Trial: 15378354
Drug: Orlistat (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat (120 mg tid) with conventional treatment
Trial: 15378354
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (conventional treatment alone)
Trial: 12575970
Drug: Captopril (225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (225 mg/day) before treatment
Trial: 12575970
Drug: Captopril (225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (225 mg/day) after treatment
Trial: 12575970
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion (0.154 mol/l at 8 ml/kg/h for 4 h) before captopril
Trial: 629218
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation of 300 mg administered daily from the 20th week of gestation until term
Trial: 629218
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation of 600 mg administered daily from the 20th week of gestation until term
Trial: 25675061
Drug: Dexmedetomidine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (5 mcg) with 3 mL of 0.5% hyperbaric bupivacaine
Trial: 25675061
Drug: Midazolam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (1 mg) with 3 mL of 0.5% hyperbaric bupivacaine
Trial: 25675061
Drug: Control (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0.5 mL of 0.9% saline) with 3 mL of 0.5% hyperbaric bupivacaine
Trial: 15477437
Drug: Vehicle-control solution
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle-control solution
Trial: 9990211
Drug: Patient-controlled sedation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled sedation (PCS) with propofol (bolus: 0.2 mg.kg‐1, lockout time: 3 min)
Trial: 9990211
Drug: Anesthesiologist-controlled sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anesthesiologist-controlled sedation (ACS) with propofol (continuous infusion)
Trial: 29061081
Drug: Trazodone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone (100 mg)
Trial: 23756425
Drug: Septilin® tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Septilin® tablets for two weeks following scaling and root planing
Trial: 20058594
Drug: Enalapril 10
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10 mg plus folic acid 0.4 mg daily (low-dose group)
Trial: 20058594
Drug: Enalapril 10
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10 mg combined with folic acid 0.8 mg daily (high-dose group)
Trial: 20058594
Drug: Enalapril 10
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10 mg/d alone (control)
Trial: 7661123
Drug: Combined doses
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined doses of lutein and beta-carotene
Trial: 2759842
Drug: Minimal-therapist-contact cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal-therapist-contact cognitive-behavioral therapy
Trial: 2759842
Drug: Clinic-based cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinic-based cognitive-behavioral therapy
Trial: 22230883
Drug: Oral leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral leucovorin calcium (2 mg/kg per day; maximum 50 mg per day)
Trial: 15378676
Drug: Mirtazapine (34.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine (34.1 mg daily)
Trial: 15378676
Drug: Sertraline (101.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (101.5 mg daily)
Trial: 3288801
Drug: Psychorelaxation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychorelaxation treatment (PRT) using autogenous training, biological feedback, or respiratory relaxation training techniques
Trial: 25924841
Drug: Tat 30
RxNorm normalized name: vadadustat 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tat 30 μg given 3 times
Trial: 25924841
Drug: Tat 30
RxNorm normalized name: vadadustat 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tat 30 μg
Trial: 25924841
Drug: Tat 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tat 7.5 μg or 30 μg, given 3 or 5 times monthly
Trial: 25924841
Drug: Tat 30
RxNorm normalized name: vadadustat 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tat 30 μg, 3x
Trial: 21311365
Drug: Creatine (CR)
DrugBank: Creatine (DB00148)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Creatine (CR) supplementation (20 g·d(‐1) for 1 week and 5 g·d(‐1) thereafter)
Trial: 17604500
Drug: Systemic agents
RxNorm normalized name: ANTIACNE AGENTS,SYSTEMIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic agents such as IFN‐alpha or cytotoxic chemotherapy
Trial: 17604500
Drug: Streptozocin-based therapy
RxNorm normalized name: Streptozocin
DrugBank: Streptozocin (DB00428)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Streptozocin-based therapy
Trial: 17604500
Drug: Agents targeting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agents targeting the VEGF pathway and mammalian target of rapamycin
Trial: 15366593
Drug: Tongluo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tongluo capsule (TLC)
Trial: 9563981
Drug: Intravenous streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous streptokinase (1.5 MU in 1 hour)
Trial: 9563981
Drug: Oral aspirin
RxNorm normalized name: aspirin Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral aspirin (162 mg daily for 1 month)
Trial: 9563981
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of streptokinase and one month of aspirin
Trial: 2589003
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose
Trial: 9564446
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose
Trial: 31526791
Drug: Pelvic floor
RxNorm normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic floor muscle training by a physical therapist (12 weekly sessions starting at ∼9 weeks postpartum)
Trial: 31077065
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium 75 mg/1 mL solution administered as a 5-s intravenous bolus